Posted by Michael Wonder on 31 Jan 2023
Amjevita (adalimumab-atto), first biosimilar to Humira, now available in the United States
31 January 2023 - Four years of real world experience in more than 300,000 patients and over 60 countries.
Amgen today announced Amjevita (adalimumab-atto), a biosimilar to Humira (adalimumab), is now available in the United States. Amjevita was the first biosimilar to Humira approved by the US FDA, in 2016.
Amjevita (40 mg) is available at a list price (wholesale acquisition cost) 55% below the current Humira list price. Amjevita is also available at a list price 5% below the current Humira list price.
